open access
Common Methylenetetrahydrofolate Reductase Polymorphisms (A1298C & C677T) in Ectopic Trophoblasts and Methotrexate Treatment Failure in Tubal Pregnancies
Affiliations- Department of Obstetrics and Gynecology, Adnan Menderes University Hospital, Aytepe, 09100 Aydin, Türkiye
- Department of Pathology, Adnan Menderes University Hospital, Aytepe, 09100 Aydin, Türkiye
- Department of Biostatistics, Adnan Menderes University Faculty of Medicine, Aytepe, 09100 Aydin, Türkiye
open access
Abstract
Objectives: The success rate of methotrexate (MTX) therapy varies among tubal ectopic pregnancies. Common
methylenetetrahydrofolate reductase (MTHFR) polymorphisms (C677T&A1298C) have been suggested to alter MTX effect. This study aimed to assess and compare MTX treatment failure rates with respect to MTHFR polymorphisms in trophoblasts of ectopic tubal pregnancies.
Material and methods: A retrospective chart review of tubal ectopic pregnancies was conducted and 34 eligible cases were found. Paraffinized blocks of ectopic trophoblastic tissues were retrieved from the archives of pathology department.
Common MTHFR polymorphisms were studied on microdissected trophoblastic tissues. Sixteen cases with history of failed MTX therapy (study group) and 18 control cases were compared for their pertinent clinical characteristics and common MTHFR polymorphisms (C677T&A1298) data.
Results: In the study group, there were 8 (50%) C677T single nucleotide polymorphisms (SNP) and 9 (56.7%) A1298C SNP. Polymorphism rates were not found to be different between two groups for neither polymorphism (p > 0.05 for both). Number of compound heterozygotes was 3 (18.7%) in study group and 5 (27.7%) in controls (p = 0.693). In addition, MTHFR polymorphism presence seemed to have no effect on interval serum β-hCG concentration change in MTX-fail group (p=0.693).
Conclusions: Our data implied that common MTHFR polymorphisms of ectopic trophoblastic tissue are not associated with MTX failure in patients with tubal pregnancies. Additionally, serum β-hCG concentration changes caused by MTX treatment and studied MTHFR polymorphisms are likely independent.
Abstract
Objectives: The success rate of methotrexate (MTX) therapy varies among tubal ectopic pregnancies. Common
methylenetetrahydrofolate reductase (MTHFR) polymorphisms (C677T&A1298C) have been suggested to alter MTX effect. This study aimed to assess and compare MTX treatment failure rates with respect to MTHFR polymorphisms in trophoblasts of ectopic tubal pregnancies.
Material and methods: A retrospective chart review of tubal ectopic pregnancies was conducted and 34 eligible cases were found. Paraffinized blocks of ectopic trophoblastic tissues were retrieved from the archives of pathology department.
Common MTHFR polymorphisms were studied on microdissected trophoblastic tissues. Sixteen cases with history of failed MTX therapy (study group) and 18 control cases were compared for their pertinent clinical characteristics and common MTHFR polymorphisms (C677T&A1298) data.
Results: In the study group, there were 8 (50%) C677T single nucleotide polymorphisms (SNP) and 9 (56.7%) A1298C SNP. Polymorphism rates were not found to be different between two groups for neither polymorphism (p > 0.05 for both). Number of compound heterozygotes was 3 (18.7%) in study group and 5 (27.7%) in controls (p = 0.693). In addition, MTHFR polymorphism presence seemed to have no effect on interval serum β-hCG concentration change in MTX-fail group (p=0.693).
Conclusions: Our data implied that common MTHFR polymorphisms of ectopic trophoblastic tissue are not associated with MTX failure in patients with tubal pregnancies. Additionally, serum β-hCG concentration changes caused by MTX treatment and studied MTHFR polymorphisms are likely independent.
Keywords
tubal pregnancy; methotrexate; methylenetetrahydrofolate reductase; polymorphism; trophoblast
About this articleTitle
Common Methylenetetrahydrofolate Reductase Polymorphisms (A1298C & C677T) in Ectopic Trophoblasts and Methotrexate Treatment Failure in Tubal Pregnancies
Journal
Issue
Article type
Research paper
Pages
536-540
Published online
2018-10-31
Page views
1786
Article views/downloads
1151
DOI
Pubmed
Bibliographic record
Ginekol Pol 2018;89(10):536-540.
Keywords
tubal pregnancy
methotrexate
methylenetetrahydrofolate reductase
polymorphism
trophoblast
Authors
Emre Zafer
Nesibe Kahraman Cetin
Ozgur Deniz Turan
Evrim Kardelen
Imran Kurt Omurlu
Hasan Yuksel
References (27)- Stulberg D, Cain L, Dahlquist I, et al. Ectopic pregnancy rates and racial disparities in the Medicaid population, 2004–2008. Fertility and Sterility. 2014; 102(6): 1671–1676.
- Creanga A, Shapiro-Mendoza C, Bish C, et al. Trends in Ectopic Pregnancy Mortality in the United States. Obstetrics & Gynecology. 2011; 117(4): 837–843.
- NCBI (National Center for Biotechnology Information). Encyclopedia of Genetics, Genomics, Proteomics and Informatics. 2016: 1325–1325.
- Qiu Qi, Huang J, Lin Y, et al. Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis. Medicine. 2017; 96(11): e6337.
- Umerez M, Gutierrez-Camino Á, Muñoz-Maldonado C, et al. MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy. Pharmacogenomics and Personalized Medicine. 2017; Volume10: 69–78.
- Kang SS, Wong PW, Susmano A, et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991; 48(3): 536–545.
- Fan H, Li Y, Zhang Li, et al. Lack of association between MTHFR A1298C polymorphism and outcome of methotrexate treatment in rheumatoid arthritis patients: evidence from a systematic review and meta-analysis. International Journal of Rheumatic Diseases. 2017; 20(5): 526–540.
- Rai V, Yadav U, Kumar P, et al. Methylenetetrahydrofolate reductase A1298C genetic variant& risk of schizophrenia: A meta-analysis. Indian J Med Res. 2017; 145(4): 437–447.
- Yuan Ye, Yu X, Niu F, et al. Genetic polymorphism of methylenetetrahydrofolate reductase as a potential risk factor for congenital heart disease. Medicine. 2017; 96(23): e7057.
- Li A, Shi Y, Xu L, et al. A possible synergistic effect of MTHFR C677T polymorphism on homocysteine level variations increased risk for ischemic stroke. Medicine. 2017; 96(51): e9300.
- Kutuk M, Subasioglu A, Uludag S, et al. The effect of parental 5,10-methylenetetrahydrofolate reductase 677C/T and 1298A/C gene polymorphisms on response to single-dose methotrexate in tubal ectopic pregnancy. The Journal of Maternal-Fetal & Neonatal Medicine. 2016; 30(10): 1232–1237.
- Diagnosis and Management of Ectopic Pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology. 2016; 123(13): e15–e55.
- Faoro V, Stanta G. Manual Microdissection. Guidelines for Molecular Analysis in Archive Tissues. 2011: 21–22.
- Song T, Kim M, Kim ML, et al. Single-dose versus two-dose administration of methotrexate for the treatment of ectopic pregnancy: a randomized controlled trial. Human Reproduction. 2015: dev312.
- Yuk JS, Lee J, Park W, et al. Systematic review and meta-analysis of single-dose and non-single-dose methotrexate protocols in the treatment of ectopic pregnancy. International Journal of Gynecology & Obstetrics. 2018; 141(3): 295–303.
- Qu J, Usui H, Kaku H, et al. Presence of the methylenetetrahydrofolate reductase gene polymorphism MTHFR C677T in molar tissue but not maternal blood predicts failure of methotrexate treatment for low-risk gestational trophoblastic neoplasia. European Journal of Pharmacology. 2017; 794: 85–91.
- Lasecka L, Dixon P, Molokhia M, et al. 667C>T and 1298A>C polymorphisms of MTHFR do not predict response to methotrexate in patients with gestational trophoblastic neoplasia. Gynecologic Oncology. 2011; 123(3): 605–609.
- Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics. 2002; 12(3): 183–190.
- Kurzawski M, Pawlik A, Safranow K, et al. 677C>T and 1298A>CMTHFRpolymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics. 2007; 8(11): 1551–1559.
- Sazci A, Ergul E, Kaya G, et al. Genotype and allele frequencies of the polymorphic methylenetetrahydrofolate reductase gene in Turkey. Cell Biochemistry and Function. 2004; 23(1): 51–54.
- Barnhart K, Gosman G, Ashby R, et al. The Medical Management of Ectopic Pregnancy. Obstetrics & Gynecology. 2003; 101(4): 778–784.
- Menon S, Colins J, Barnhart K. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertility and Sterility. 2007; 87(3): 481–484.
- Hajenius P, Mol F, Mol B, et al. Interventions for tubal ectopic pregnancy. Cochrane Database of Systematic Reviews. 2007.
- Lipscomb G, Givens V, Meyer N, et al. Comparison of multidose and single-dose methotrexate protocols for the treatment of ectopic pregnancy. American Journal of Obstetrics and Gynecology. 2005; 192(6): 1844–1847.
- Takacs P, Rodriguez L, Laibl V, et al. Relationship of high pretreatment folic acid level and failure of methotrexate in ectopic pregnancy: a pilot study. J Reprod Med. 2004; 49(9): 713–716.
- Zhang B, Denomme M, White C, et al. Both the folate cycle and betaine-homocysteine methyltransferase contribute methyl groups for DNA methylation in mouse blastocysts. The FASEB Journal. 2015; 29(3): 1069–1079.
- Shah T, Joshi K, Mishra S, et al. Molecular and cellular effects of vitamin B12 forms on human trophoblast cells in presence of excessive folate. Biomedicine & Pharmacotherapy. 2016; 84: 526–534.
